Mevo Health review

The clinical writing here is better than the pricing. Both molecules get their own description, the mechanism difference between a single-receptor agonist and a dual one is explained rather than asserted, and the account of how GLP-1s affect gastric emptying and satiety is accurate and free of the usual overstatement. You arrive understanding the choice in front of you. Then the pricing collapses that choice into one number. A single floor spanning both drugs cannot be true of both at the same price, because the dual agonist reliably costs a seller more, so either the figure belongs to the cheaper molecule with the other dearer by an unstated amount, or it describes a starting configuration the page does not set out. Either way the arithmetic you were just equipped to do cannot be done. The figure is also a floor with no ceiling, and no milligram sits behind it, which leaves the structure underneath unknowable — a starting price is equally consistent with a flat plan, a per-dose ladder, or a ladder that steepens sharply. The careful phrasing about a plan that may include a GLP-1 is accurate about how prescribing works and is worth noticing: what is priced is a program, not a guarantee of a particular drug.

Vs median

$24/mo above the $175 median across the 299 of 548 programs here that publish a plain monthly rate

Market

$59–$1,300/mo is the full published spread on this site

Structure

Standard plan, self-directed low dose

Consult

Included in the price

Dietitian

Not confirmed

Labs

Not required

Pricing

Check plan terms

Mevo Health does not publicly identify the pharmacy that fills its prescriptions. No bloodwork is required before you start. A clinician review is included in the price.

The clinical writing here is better than the pricing. Both molecules get their own description, the mechanism difference between a single-receptor agonist and a dual one is explained rather than asserted, and the account of how GLP-1s affect gastric emptying and satiety is accurate and free of the usual overstatement. A reader arrives understanding the choice in front of them. Then the pricing collapses that choice into one number. A single floor spanning both drugs cannot be true of both at the same price, because the dual agonist reliably costs a seller more, so either the figure belongs to the cheaper molecule with the other dearer by an unstated amount, or it describes a starting configuration the page does not set out. Either way the arithmetic a reader was just equipped to do cannot be done. The figure is also a floor with no ceiling, and no milligram sits behind it, which leaves the structure underneath unknowable — a starting price is equally consistent with a flat plan, a per-dose ladder, or a ladder that steepens sharply. The careful phrasing about a plan that may include a GLP-1 is accurate about how prescribing works and is worth noticing: what is priced is a program, not a guarantee of a particular drug.

One floor covers both molecules, so the cheaper of the two cannot be identified.

• No ceiling is published and no dose sits behind the figure.
• The wording promises a plan that may include a GLP-1, not that one will be prescribed.

Mevo Health is one of 548 low-dose GLP-1 programs compared on this site, and 299 of them publish a monthly rate you can read before signing up. The full list puts every published price in one place, with the companies that pay us listed first — something we state there, on the page it applies to.

Intentional GLP-1 microdosing is off-label and unproven — no randomized trial has established that a sub-label dose does anything, and any dose belongs with a clinician who knows your history. If you are going to have that conversation, have it with real numbers.

• What microdosing GLP-1 costs
• Microdosing semaglutide
• Microdosing tirzepatide
• The true annual cost of a plan